Citius Pharmaceuticals, Inc. 8-K

What Happened Citius Pharmaceuticals, Inc. (CTXR) reported on June 1, 2026 (Form 8-K, Item 8.01) that its wholly owned subsidiary, Citius Oncology, Inc., issued a press release announcing the presentation of clinical data at the Annual Meeting of the American Society of Clinical Oncology (ASCO). The press release is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Press release dated June 1, 2026 issued by Citius Oncology, Inc. (furnished as Exhibit 99.1).
• Event: presentation of clinical data at the ASCO Annual Meeting (American Society of Clinical Oncology).
• Reported on Form 8-K under Item 8.01 (Other Events); exhibit filing included.

Why It Matters A scheduled presentation of clinical data at ASCO is a development milestone for a clinical-stage company: it provides a formal forum to disclose trial results to oncologists, researchers and investors. While the 8-K itself does not provide the data details, the announcement increases visibility on the company’s clinical progress and is a material event investors monitor for updates on drug development and potential future regulatory or commercial implications.